HK1216611A1 - 白蛋白和紫杉醇的納米顆粒組合物 - Google Patents

白蛋白和紫杉醇的納米顆粒組合物 Download PDF

Info

Publication number
HK1216611A1
HK1216611A1 HK16104504.3A HK16104504A HK1216611A1 HK 1216611 A1 HK1216611 A1 HK 1216611A1 HK 16104504 A HK16104504 A HK 16104504A HK 1216611 A1 HK1216611 A1 HK 1216611A1
Authority
HK
Hong Kong
Prior art keywords
albumin
paclitaxel
nanoparticle compositions
compositions
nanoparticles
Prior art date
Application number
HK16104504.3A
Other languages
English (en)
Chinese (zh)
Inventor
．德賽
N．P．德赛
Original Assignee
阿布拉科斯生物科学有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿布拉科斯生物科学有限公司 filed Critical 阿布拉科斯生物科学有限公司
Publication of HK1216611A1 publication Critical patent/HK1216611A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16104504.3A 2012-12-28 2013-12-19 白蛋白和紫杉醇的納米顆粒組合物 HK1216611A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US61/747,123 2012-12-28
US13/794,705 2013-03-11
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Publications (1)

Publication Number Publication Date
HK1216611A1 true HK1216611A1 (zh) 2016-11-25

Family

ID=51017455

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104504.3A HK1216611A1 (zh) 2012-12-28 2013-12-19 白蛋白和紫杉醇的納米顆粒組合物

Country Status (19)

Country Link
US (2) US20140186447A1 (cg-RX-API-DMAC7.html)
EP (1) EP2938340A4 (cg-RX-API-DMAC7.html)
JP (2) JP2016504362A (cg-RX-API-DMAC7.html)
KR (1) KR20150100903A (cg-RX-API-DMAC7.html)
CN (1) CN105007912A (cg-RX-API-DMAC7.html)
AU (1) AU2013370955B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015015319A2 (cg-RX-API-DMAC7.html)
CA (1) CA2896288A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150386A (cg-RX-API-DMAC7.html)
HK (1) HK1216611A1 (cg-RX-API-DMAC7.html)
IL (1) IL239593A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015008361A (cg-RX-API-DMAC7.html)
NI (1) NI201500090A (cg-RX-API-DMAC7.html)
NZ (1) NZ630912A (cg-RX-API-DMAC7.html)
PH (1) PH12015501486B1 (cg-RX-API-DMAC7.html)
RU (1) RU2663687C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201505111TA (cg-RX-API-DMAC7.html)
WO (1) WO2014105644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504762B (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
PT2155188E (pt) * 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
SMT201900751T1 (it) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
ES2675212T3 (es) 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
ES2819204T3 (es) 2011-04-28 2021-04-15 Abraxis Bioscience Llc Administración intravascular de composiciones de nanopartículas y usos de las mismas
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US9585960B2 (en) 2011-12-14 2017-03-07 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
KR102245421B1 (ko) 2013-05-30 2021-04-29 큐라디즘 약학적 조성물, 이의 제조방법 및 이의 용도
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
PT3229843T (pt) * 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
TW201628610A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
HUE062561T2 (hu) 2014-11-25 2023-11-28 Curadigm Sas Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai
BR112017010953B1 (pt) 2014-11-25 2024-01-16 Curadigm Sas Composição farmacêutica contendo a combinação de um lipossoma e um carreador que compreende um composto farmacêutico
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP2018516256A (ja) 2015-05-28 2018-06-21 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 治療用ワクチンとしての使用のためのナノ粒子
CN108024999A (zh) 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) * 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
AU2017318668A1 (en) 2016-09-01 2019-03-21 Mayo Foundation For Medical Education And Research Carrier-PD-L1 binding agent compositions for treating cancers
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
MX2019002564A (es) 2016-09-06 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR102486057B1 (ko) 2016-09-06 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
SG11202001802YA (en) * 2017-10-03 2020-03-30 Crititech Inc Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
CN112188892A (zh) 2018-03-20 2021-01-05 阿布拉科斯生物科学有限公司 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
CN115003284A (zh) * 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物
KR20220113699A (ko) * 2019-11-11 2022-08-16 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물에 대한 바이오마커
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
KR102526793B1 (ko) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법
EP4375659B1 (en) * 2022-11-28 2025-03-26 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1100494A1 (en) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
ES2577024T3 (es) * 2009-08-25 2016-07-12 Abraxis Bioscience, Llc Terapia combinada con composiciones de nanopartículas de taxano e inhibidores de Hedgehog
ES2675212T3 (es) * 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Also Published As

Publication number Publication date
SG11201505111TA (en) 2015-07-30
JP2018087241A (ja) 2018-06-07
WO2014105644A1 (en) 2014-07-03
PH12015501486B1 (en) 2020-12-16
BR112015015319A2 (pt) 2017-07-11
ZA201504762B (en) 2016-10-26
US20190192477A1 (en) 2019-06-27
EP2938340A4 (en) 2016-08-03
PH12015501486A1 (en) 2015-09-21
RU2015131141A (ru) 2017-02-03
NZ630912A (en) 2017-05-26
CN105007912A (zh) 2015-10-28
IL239593A0 (en) 2015-08-31
US20140186447A1 (en) 2014-07-03
CR20150386A (es) 2015-10-07
AU2013370955A1 (en) 2015-07-16
RU2663687C2 (ru) 2018-08-08
AU2013370955B2 (en) 2018-12-06
CA2896288A1 (en) 2014-07-03
JP2016504362A (ja) 2016-02-12
NI201500090A (es) 2015-12-22
MX2015008361A (es) 2016-03-11
EP2938340A1 (en) 2015-11-04
KR20150100903A (ko) 2015-09-02

Similar Documents

Publication Publication Date Title
HK1216611A1 (zh) 白蛋白和紫杉醇的納米顆粒組合物
IL258055B (en) Preparations and methods for administering a modified dendrimer nanoparticle vaccine
IL231168B (en) Benzenesulfonamide history of quinoxaline, their pharmaceutical preparations and their use for the preparation of a drug for the treatment of cancer
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
HK1220405A1 (zh) 治疗膀胱癌的方法
MX350589B (es) Copolimeros funcionales pla-peg, las nanoparticulas de los mismos, su preparacion y su uso para la administracion dirigida de farmacos e imagenologia.
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL238662A (en) Bandostatin derivatives, containing them and used to treat cancer
HK1219231A1 (zh) 治疗儿童实体瘤的方法
EP3129062A4 (en) Targeted polymerized nanoparticles for cancer treatment
EP3013320A4 (en) Docetaxel polymeric nanoparticles for cancer treatment
WO2010065329A3 (en) Nanoparticles for cancer treatment
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
EP3220895A4 (en) The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
BR112014015753A2 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
WO2012040331A3 (en) Multistage nanoparticles
WO2017079403A3 (en) Polymeric nanoparticles
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
WO2013038195A3 (en) Pharmaceutical nanoparticle compositions
EP3291838A4 (en) Anionic nanoparticles for use in the delivery of anionic small molecule drugs
EP3116513A4 (en) Pharmaceutical compositions comprising rna and use for treating cancer
HK40009757A (en) Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles
HK40025095A (en) Nanoparticle compositions, methods of fabrication, and use for drug delivery
HK40007085A (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer